Your browser doesn't support javascript.
loading
Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.
Lee, Bianca J; Boyer, Jacob A; Burnett, G Leslie; Thottumkara, Arun P; Tibrewal, Nidhi; Wilson, Stacy L; Hsieh, Tientien; Marquez, Abby; Lorenzana, Edward G; Evans, James W; Hulea, Laura; Kiss, Gert; Liu, Hui; Lee, Dong; Larsson, Ola; McLaughlan, Shannon; Topisirovic, Ivan; Wang, Zhengping; Wang, Zhican; Zhao, Yongyuan; Wildes, David; Aggen, James B; Singh, Mallika; Gill, Adrian L; Smith, Jacqueline A M; Rosen, Neal.
Afiliación
  • Lee BJ; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Boyer JA; Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
  • Burnett GL; Program in Molecular Pharmacology, Department of Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), New York, NY, USA.
  • Thottumkara AP; Department of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Tibrewal N; Department of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Wilson SL; Department of Discovery Technologies, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Hsieh T; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Marquez A; Department of Discovery Technologies, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Lorenzana EG; Department of Discovery Technologies, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Evans JW; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Hulea L; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Kiss G; Gerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, Lady Davis Institute, McGill University, Montréal, QC, Canada.
  • Liu H; Département de Médecine, Département de Biochimie et Médecine Moléculaire, Université de Montréal, Montréal, QC, Canada.
  • Lee D; Maisonneuve-Rosemont Hospital Research Centre, Montréal, QC, Canada.
  • Larsson O; Department of Discovery Technologies, Revolution Medicines, Inc., Redwood City, CA, USA.
  • McLaughlan S; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden.
  • Topisirovic I; Department of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Wang Z; Science for Life Laboratory, Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden.
  • Wang Z; Gerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, Lady Davis Institute, McGill University, Montréal, QC, Canada.
  • Zhao Y; Gerald Bronfman Department of Oncology and Departments of Biochemistry and Experimental Medicine, Lady Davis Institute, McGill University, Montréal, QC, Canada.
  • Wildes D; Department of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Aggen JB; Department of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Singh M; Department of Non-clinical Development and Clinical Pharmacology, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Gill AL; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Smith JAM; Department of Chemistry, Revolution Medicines, Inc., Redwood City, CA, USA.
  • Rosen N; Department of Biology, Revolution Medicines, Inc., Redwood City, CA, USA.
Nat Chem Biol ; 17(11): 1209, 2021 Nov.
Article en En | MEDLINE | ID: mdl-34616097

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Nat Chem Biol Asunto de la revista: BIOLOGIA / QUIMICA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Nat Chem Biol Asunto de la revista: BIOLOGIA / QUIMICA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos